The expression of ROMO1 was also found to be associated with tumor-infiltrating immune cells, leading to changes in the tumor microenvironment and further increasing tumor heterogeneity; drug sensitivity analysis revealed that nutlin-3 and fluorouracil could be used as potential therapeutic agents for ROMO1. This evidence concerns the gene ROMO1 and neoplasm.